復星醫藥(600196.SH):子公司擬參設安吉基金、徐州基金兩個平行基金 以定投腫瘤及非腫瘤治療等領域
格隆匯11月24日丨復星醫藥(600196.SH)公佈,為持續加強集團對於前沿創新藥研發項目的早期介入,並多元化引入外部資本,公司控股子公司/企業擬參與設立目標基金(該基金由安吉基金、徐州基金兩個平行基金組成),用以定向投資①非腫瘤治療領域(如自身免疫系統疾病、中樞神經系統疾病和代謝疾病)及②腫瘤治療領域自研或引入的早期創新藥項目。其中:
1、控股子公司/企業復耀瀛創、寧波復瀛擬與其他2方投資人共同設立安吉基金(“參與設立安吉基金”)。
安吉基金計劃募集資金人民幣5億元,其中:復耀瀛創(作為GP)、寧波復瀛(作為LP)擬分別以現金出資人民幣500萬元、1.65億元認繳安吉基金中的等值財產份額。
2、控股子公司/企業復耀瀛創、寧波復瀛擬與其他3方投資人共同設立徐州基金(“參與設立徐州基金”)。
徐州基金計劃募集資金人民幣5億元,其中:復耀瀛創(作為GP)、寧波復瀛(作為LP)擬分別以現金出資人民幣500萬元、1.65億元認繳徐州基金中的等值財產份額。
此次投資遵循集團創新戰略,旨在拓展集團大健康領域非腫瘤治療領域(如自身免疫系統疾病、中樞神經系統疾病和代謝疾病)創新藥及腫瘤治療領域創新藥管線,加強創新技術和產品的儲備和佈局。
此次投資完成後,目標基金將納入集團合併報表範圍。
Follow us
Find us on
Facebook,
Twitter ,
Instagram, and
YouTube or frequent updates on all things investing.Have a financial topic you would like to discuss? Head over to the
uSMART Community to share your thoughts and insights about the market! Click the picture below to download and explore uSMART app!

Disclaimers
uSmart Securities Limited (“uSmart”) is based on its internal research and public third party information in preparation of this article. Although uSmart uses its best endeavours to ensure the content of this article is accurate, uSmart does not guarantee the accuracy, timeliness or completeness of the information of this article and is not responsible for any views/opinions/comments in this article. Opinions, forecasts and estimations reflect uSmart’s assessment as of the date of this article and are subject to change. uSmart has no obligation to notify you or anyone of any such changes. You must make independent analysis and judgment on any matters involved in this article. uSmart and any directors, officers, employees or agents of uSmart will not be liable for any loss or damage suffered by any person in reliance on any representation or omission in the content of this article. The content of the article is for reference only and does not constitute any offer, solicitation, recommendation, opinion or guarantee of any securities, virtual assets, financial products or instruments. Regulatory authorities may restrict the trading of virtual asset-related ETFs to only investors who meet specified requirements. Any calculations or images in the article are for illustrative purposes only.
Investment involves risks and the value and income from securities may rise or fall. Past performance is not indicative of future performance. Please carefully consider your personal risk tolerance, and consult independent professional advice if necessary.